Integration Framework of MES Toward Data Security Interoperation

© 2020, Springer Nature Switzerland AG. The core problem of the application of MES (Manufacturing Execution System) in intelligent manufacturing systems is integration, which solves the problem of the data interoperation between the distributed manufacturing systems. The previous researches on MES integration rarely considered the problem of system data security access. A three-level data security access mechanism based on the independence of the system administrators, security administrators, and security auditors is proposed which integrated into the MES integration framework to guarantee the business and engineering data security access for the related distributed clients. The principle is using the domain to make the logical isolation for different clients and data sources and applying the pre-defined data sharing rules for safe access. In the proposed MES integration framework model, the data interoperation between MES and the engineering software systems is discussed which includes ERP (Enterprise Resource Management), CAPP (Computer Aided Process Planning), DNC (Distribution Numerical Control), WMS (Warehouse Management System), and SCADA (Supervisory Control and Data Acquisition), etc., the implementation method of personalized data display GUI is discussed as well. The study is based on the KMMES developed by Wuhan KM-Software of China, and it has been deployed in over forty companies from the sections of aerospace, automotive, shipbuilding and other industries

Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)

Background: Predictive factors of rituximab efficacy and its effect on the immune system are still not defined. Patients and methods: Three hundred and six patients with follicular or mantle cell lymphoma received four weekly doses of rituximab (induction) and no further treatment (arm A) or four more doses at 2-month intervals (arm B). Results: Response rate to induction was 44%. Independent predictive factors for response were disease bulk <5 cm, follicular histology, normal hemoglobin and low lymphocyte count. Factors associated with event-free survival (EFS) were having responded to induction, having received not more than one line of therapy, Ann Arbor stage I-III, high lymphocyte count, disease bulk <5 cm, Fc-gamma receptor genotype VV and receiving prolonged treatment. B cells were suppressed by treatment but recovered after a median of 12 months in arm A and 18 months in arm B. The median IgM level after 1 year was normal in arm A but was decreased to 73% of baseline in arm B. We observed 24 serious adverse events, equally distributed between arms. Ten patients receiving induction only and six patients receiving prolonged treatment developed a second tumor. Conclusions: We defined the characteristics predicting response and EFS to rituximab. Prolonged treatment results in longer EFS at the cost of a longer reduction in B cell and IgM levels, but without additional clinical toxicit

Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study

Background: To assess the activity and toxicity of 2-chlorodeoxyadenosine (cladribine, CDA) given by subcutaneous bolus injections to patients with hairy cell leukemia (HCL). Patients and methods: Sixty-two eligible patients with classic or prolymphocytic HCL (33 non-pretreated patients, 15 patients with relapse after previous treatment, and 14 patients with progressive disease during a treatment other than CDA) were treated with CDA 0.14 mg/kg/day by subcutaneous bolus injections for five consecutive days. Response status was repeatedly assessed according to the Consensus Resolution criteria. Results: Complete and partial remissions were seen in 47 (76%) and 13 (21%) patients, respectively, for a response rate of 97%. All responses were achieved with a single treatment course. Most responses occurred early (i.e. within 10 weeks) after start of CDA therapy, but response quality improved during weeks and even months after treatment completion. The median time to treatment failure for all patients was 38 months. Leukopenia was the main toxicity. Granulocyte nadir (median 0.2 × 109/l) was strongly associated with the incidence of infections (P = 0.0013). Non-specific lymphopenia occurred early after CDA treatment, and normal lymphocytes recovered slowly over several months. No significant associations were found between infections and nadir count of lymphocytes or any lymphocyte subpopulation. No opportunistic infections were observed. Conclusions: One course of CDA given by subcutaneous bolus injections is very effective in HCL. The subcutaneous administration is more convenient for patients and care providers, and has a similar toxicity profile to continuous intravenous infusion. The subcutaneous administration of CDA is a substantial improvement and should be offered to every patient with HCL requiring treatment with CD

Life expectancy of young adults with follicular lymphoma

FL patients younger than 40 have a median OS of 24 years and their outcome improved over time. However, they still have a significantly shorter life expectancy when compared with that of an age-matched general healthy population. FL in young adults, differently from paediatric FL, does not seem to represent a distinct entit